CML: The good, the better, and the difficult choices

Abstract

In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).